MDXG mimedx.com Earnings growth forecast for next year

The diversification of placental biologics for surgery and orthopedics reduces risks for MiMedx Group, Inc. (MDXG), confirming the trajectory of forward expectations for net income. The value of 114.10 indicates the current level of this metric. MiMedx Group, Inc. (MDXG) is developing partnerships with hospitals to implement regenerative therapy. Standard environmental controls and production sterility complement the business's operating model.

MiMedx Group (MDXG): Expected net earnings per share growth next year from 07/04/2022 to 11/15/2026

MDXG (MiMedx Group Inc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:

Stock Price MiMedx Corp|MDXG - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization MiMedx Group Inc|MDXG - Total Company Value

- book capitalization indicators:

Net Assets per Single Share MiMedx|MDXG - Total Stockholders' Equity|Market Value to Book Value Ratio mimedx.com|MDXG - Aggregate Company Assets

- debt and solvency information:

- net income and valuation ratios data:

MDXG - Net Financial Result|Expected Profit MiMedx Group, Inc.|MDXG - Price to Earnings Ratio|Forward P/E Multiple MiMedx Corp|MDXG - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple MiMedx Corp|MDXG - Operating profit before amortization|Net earnings per share for the last 12 months MiMedx|MDXG - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months mimedx.com|MDXG - Earnings per share increase in current year|Earnings growth forecast for next year MiMedx Group, Inc.

- total revenue and sales volume data:

MDXG - Company Total Sales Volume|Company Projected Revenue MiMedx Group, Inc.|MDXG - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio MiMedx

Initial company analysis:MDXG, mimedx.com

Portfolio managers evaluate the operating model of MiMedx Group, Inc. (MDXG) through a consensus earnings forecast, which measures market confidence in the business's ability to scale net income over the short term. By analyzing the projected earnings growth for the coming year, investors can determine how effectively the ambitious strategy for implementing placental biomaterials and the engagement of a highly skilled surgical staff convert into the asset's future financial stability.

Analysis of competing companies